RYVYL Inc. (RVYL): Nasdaq/NYSE listing notice — RYVYL receives Nasdaq deficiency notice for minimum bid price non-compliance

RYVYL Inc.

Nasdaq letter dated Dec 5, 2022; closing bid below $1.00 for 30 consecutive business days.
Company has 180 days (until June 5, 2023) to regain compliance with Minimum Bid Requirement.
To cure, RVYL stock must close at or above $1.00 for at least 10 consecutive trading days.
If not compliant by June 5, 2023, Company may seek second 180-day period or face delisting.
No immediate impact on listing; RVYL shares continue trading on Nasdaq; reverse split not under consideration.

item 3.01 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

RYVYL Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

December 5, 2022, RYVYL Inc. (the “Company”) received a deficiency letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, based upon the closing bid price of the Company’s common stock, par value $0.001 per share (“Common Stock”), for the last 30 consecutive business days, the Company is not currently in compliance with the requirement to maintain a minimum bid price of $1.00 per share for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Requirement”).

View on SEC.gov

50 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

RYVYL Inc. filing history →

Source: SEC EDGAR

accession 0001185185-22-001399

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.